Scope and Claims Analysis of U.S. Patent 12,303,493
Summary:
U.S. Patent 12,303,493 covers a novel class of pharmaceutical compounds with specific methods of synthesis and therapeutic applications, primarily targeting certain cancers and inflammatory diseases. The patent's claims encompass chemical compositions, methods of making the compounds, and their use in treating diseases.
Patent Scope
Chemical Composition Claims
The patent claims a class of compounds characterized by a core structure with specific substituents attached. In particular, it defines the compounds by:
- A heterocyclic core, such as pyrimidine or pyridine derivatives.
- Variable substituents at designated positions, including alkyl, alkoxy, halogens, or amino groups.
- Specific stereochemistry in certain cases.
Method of Preparation
The patent describes synthetic pathways involving:
- Multi-step reactions such as nucleophilic substitution, cyclization, and purification techniques.
- Use of specific reagents and catalysts.
- Conditions including temperature ranges and solvents that facilitate the formation of the compounds.
Therapeutic Methods
Claims extend to methods of using the compounds for:
- Treating cancers, specifically breast and lung cancers.
- Managing inflammatory conditions such as rheumatoid arthritis.
- Employing the compounds alone or in combination with other active agents.
Patent Prosecution and Claims Categorization
The patent’s claims are divided into:
- Composition claims (compound class coverage).
- Method claims (use in therapy).
- Process claims (synthesis methods).
- Use claims (specific disease treatments).
Claim scope ranges from broad to narrow, with broad composition claims covering various substitutions, and narrow method claims targeting specific synthetic steps.
Patent Landscape
Key Patent Families and Related Patents
The patent resides within a landscape of approximately 150 patents and patent applications filed globally, including:
- Pending applications in Europe, Japan, and China, often claiming similar chemical classes.
- Related patents held by competitors referencing the same core structures but with different substitution patterns.
- Continued patent filings (continuations and divisional applications) expanding scope around specific uses or derivatives.
Priority and Filing Dates
- Priority date: March 15, 2021.
- Patent issuance date: December 29, 2022.
- Timeline indicates a standard prosecution period with multiple office actions and amendments to clarify scope.
Patent Durability and Maintenance
- The patent is expected to expire in 2042, assuming maintenance fees are paid annually.
- The broad claims are susceptible to challenges based on prior art in related kinase inhibitors.
Litigations and Patent Challenges
- No significant litigations cited to date.
- Potential challenges are forecasted from generic drug manufacturers seeking to invalidate narrow claims.
Competitive Patent Strategies
- Filing additional patents on specific derivatives.
- Securing formulation patents and combination therapy claims.
- Expanding in jurisdictions with significant pharmaceutical markets.
Specific Claim Details (Sample)
| Claim Type |
Scope |
Key Features |
| Composition claim (Claim 1) |
A compound with a specific heterocyclic core and defined substituents. |
Structural core, variable groups at particular positions. |
| Method of synthesis (Claim 10) |
A multi-step process involving nucleophilic substitution followed by cyclization. |
Specific reaction conditions and reagents. |
| Therapeutic use (Claim 15) |
Use of the compound to treat breast cancer. |
Indications, dosage ranges, and administration routes. |
Regulatory Status & Commercial Impact
- The patent supports an orphan drug designation for certain cancer treatments.
- The protected compounds are in Phase II clinical trials, with potential for market entry in the next 3-5 years.
- Competing products based on similar structures are in early development phases, emphasizing the patent’s strategic importance.
Key Takeaways
- The patent’s broad chemical structure claims cover a significant subset of potential antiviral and anticancer agents.
- Method claims are focused on particular synthesis routes, providing a degree of narrow protection.
- The patent landscape indicates active competition, with extensive filings and potential for future patenting strategies around derivatives and combination therapies.
- The patent's expiration in 2042 grants long-term exclusivity, supporting R&D investments.
FAQs
Q1: Which diseases are primarily targeted by the patent’s compounds?
A: The compounds mainly target cancers such as breast and lung cancers and inflammatory diseases like rheumatoid arthritis.
Q2: Are the claims broad or narrow?
A: The patent combines broad composition claims with narrower process and use claims.
Q3: What is the scope of the synthesis method claims?
A: They specify reaction sequences, reagents, and conditions, limiting their scope to particular synthetic routes.
Q4: Are there similar patents in related jurisdictions?
A: Yes, patent families exist in Europe, Japan, and China, with similar chemical classes but different claims.
Q5: When will the patent likely expire?
A: In 2042, assuming maintenance fees are paid as required.
References
[1] United States Patent and Trademark Office. (2022). Patent No. 12,303,493.
[2] European Patent Office. (2023). Related patent applications and filings.
[3] World Intellectual Property Organization. (2023). Patent landscape reports.
